433 related articles for article (PubMed ID: 37305018)
1. Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.
Varisli L; Tolan V; Cen JH; Vlahopoulos S; Cen O
Oncol Res; 2022; 30(3):137-155. PubMed ID: 37305018
[TBL] [Abstract][Full Text] [Related]
2. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
3. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
4. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.
Yamamichi F; Shigemura K; Behnsawy HM; Meligy FY; Huang WC; Li X; Yamanaka K; Hanioka K; Miyake H; Tanaka K; Kawabata M; Shirakawa T; Fujisawa M
Scand J Urol; 2014 Dec; 48(6):523-32. PubMed ID: 25356787
[TBL] [Abstract][Full Text] [Related]
5. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
7. Androgen depletion up-regulates cadherin-11 expression in prostate cancer.
Lee YC; Cheng CJ; Huang M; Bilen MA; Ye X; Navone NM; Chu K; Kao HH; Yu-Lee LY; Wang Z; Lin SH
J Pathol; 2010 May; 221(1):68-76. PubMed ID: 20191612
[TBL] [Abstract][Full Text] [Related]
8. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of epithelial and mesenchymal proteins in a panel of prostate cancer cell lines.
Murali AK; Norris JS
J Urol; 2012 Aug; 188(2):632-8. PubMed ID: 22704442
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation and immunotherapy for the treatment of prostate cancer.
Gamat M; McNeel DG
Endocr Relat Cancer; 2017 Dec; 24(12):T297-T310. PubMed ID: 28814451
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
13. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.
Tsai HT; Keating NL; Van Den Eeden SK; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Smith MR; Potosky AL
J Urol; 2015 Jun; 193(6):1956-62. PubMed ID: 25524243
[TBL] [Abstract][Full Text] [Related]
14. Chronic hypoxia-induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin-B1.
Iwasaki K; Ninomiya R; Shin T; Nomura T; Kajiwara T; Hijiya N; Moriyama M; Mimata H; Hamada F
Cancer Sci; 2018 Oct; 109(10):3159-3170. PubMed ID: 30058095
[TBL] [Abstract][Full Text] [Related]
15. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
16. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
Colditz J; Rupf B; Maiwald C; Baniahmad A
Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
[TBL] [Abstract][Full Text] [Related]
17. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry.
Cary KC; Singla N; Cowan JE; Carroll PR; Cooperberg MR
J Urol; 2014 Apr; 191(4):964-70. PubMed ID: 24184370
[TBL] [Abstract][Full Text] [Related]
18. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
[TBL] [Abstract][Full Text] [Related]
19. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.
Zhu ML; Kyprianou N
FASEB J; 2010 Mar; 24(3):769-77. PubMed ID: 19901020
[TBL] [Abstract][Full Text] [Related]
20. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
Sari Motlagh R; Quhal F; Mori K; Miura N; Aydh A; Laukhtina E; Pradere B; Karakiewicz PI; Enikeev DV; Deuker M; Shariat SF
J Urol; 2021 Jan; 205(1):60-67. PubMed ID: 32856962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]